Eisai Co., Ltd. (ESALF)
OTCMKTS · Delayed Price · Currency is USD
32.30
+3.80 (13.33%)
Sep 3, 2025, 2:33 PM EDT
Eisai Employees
Eisai had 10,917 employees as of March 31, 2025. The number of employees decreased by 150 or -1.36% compared to the previous year.
Employees
10,917
Change (1Y)
-150
Growth (1Y)
-1.36%
Revenue / Employee
$509,835
Profits / Employee
$31,951
Market Cap
9.24B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 10,917 | -150 | -1.36% |
| Mar 31, 2024 | 11,067 | -9 | -0.08% |
| Mar 31, 2023 | 11,076 | -246 | -2.17% |
| Mar 31, 2022 | 11,322 | 85 | 0.76% |
| Mar 31, 2021 | 11,237 | 239 | 2.17% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Elite Pharmaceuticals | 68 |
| Tian'an Technology Group | 8 |
| Glass House Brands | 374 |
| CytoDyn | 13 |
| Northwest Biotherapeutics | 25 |
| American Oncology Network | 1,914 |
| Silence Therapeutics | 116 |
| Longduoduo Company | 49 |
Eisai News
- 5 days ago - US FDA approves injectable version of Eisai-Biogen's Alzheimer's drug - Reuters
- 5 days ago - FDA Approves Biogen, Eisai's Highly Anticipated Alzheimer's Treatment - Investor's Business Daily
- 10 days ago - Biogen Inc (BIIB) and Eisai Launch Alzheimer's Drug LEQEMBI in Europe | BIIB stock news - GuruFocus
- 27 days ago - Eli Lilly And Biogen (And Eisai): Muddying The Waters In Alzheimer's Disease - Seeking Alpha
- 4 weeks ago - Eisai Co., Ltd. 2026 Q1 - Results - Earnings Call Presentation - Seeking Alpha
- 4 weeks ago - Eisai Co., Ltd. (ESALF) Q1 2026 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Eisai/Biogen, Eli Lilly highlight long-term data backing Alzheimer’s drugs - Seeking Alpha
- 5 weeks ago - Patients still benefit from Eisai and Biogen Alzheimer's drug after four years, study finds - Reuters